CBX

  Lepu Biopharma and Miracogen have submitted the IND application for MRG006A, an anti-GPC3 ( Glypican-3 ) ADC in China, and the IND application is also expected to be submitted to the US FDA this year. MRG006A MRG006A is a GPC3-targeting ADC composed of a novel humanized IgG1 antibody conjugated to a potent topoisomerase 1 inhibitor via a peptide-based cleavable linker, with a DAR ratio of 8. MRG006A Lepu Biopharma and  Miracogen presented the results of the preclinical study of MRG006A at the 2023 AACR Annual Meeting. Highlights demonstrated its superior binding activity to GPC3-expressing cancer cell lines, rapid internalization, and potent GPC3-dependent cytotoxic activity. In 2022, Miracogen filed a patent (WO2024061305 ) covering the GPC3 ADCs and their use in cancers, including liver cancer.  The ADCs discussed in the examples included several candidates with DAR values ranging from 2 to 4, all of which were tested in the LIV#219 liver cancer PDX model. GPC3 targeting ADCs Curre